Article Text

Download PDFPDF
Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder

Statistics from Altmetric.com

Footnotes

  • Competing interests DC has research funded by Shire Pharmaceuticals and Vifor Pharma. He has received honoraria, consultancy and speaking fees from Janssen-Cilag, Eli Lilly, Medice, Novartis, Shire and Vifor Pharma, and royalties from the Oxford University Press.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.